Screener / SEC EDGAR /CIK 0000215466 /10-K filed Feb 18, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Materials · Gold Mining

Coeur Mining, Inc. CDE

Compare with peers Embed
Planned sales, announced before they happen

4 trading plans running, 3 Form 144 notices for $3.0M

10-Q, 10-K and Form 144
Plans running now 4 Aoife McGrath, Mitchell J. Krebs, Casey M. Nault, Anne Beckelheimer
Plans adopted 6 reported since May 10, 2023 Form 144 notices 3 $3.0M the sellers expected to sell

What CDE's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Feb 21, 2025 to May 8, 2028. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Aoife McGrath
Executive Vice President, Exploration
Adopted 10b5-1 plan Jun 15, 2026 10-Q Aug 5, 2026
What the company wrote
On June 15, 2026, Aoife McGrath, Executive Vice President, Exploration, adopted a new trading arrangement for the sale of the shares of the Company’s common stock (the “McGrath 10b5-1 Plan”). The McGrath 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s Insider Trading Policy and is intended to satisfy the affirmative defense requirements of Rule 10b5-1(c) under the Exchange Act. The McGrath 10b5-1 Plan provides for the sale of up to 30,000 shares of the Company’s common stock between December 18, 2026 and December 31, 2027, pursuant to terms specified in the McGrath 10b5-1 Plan.
Mitchell J. Krebs
Chairman, President and Chief Executive Officer
Adopted 10b5-1 plan Jun 1, 2026 10-Q Aug 5, 2026
What the company wrote
On June 1, 2026, Mitchell J. Krebs, Chairman, President and Chief Executive Officer, adopted a new trading arrangement for the sale of the shares of the Company’s common stock (the “Krebs 10b5-1 Plan”). The Krebs 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s Insider Trading Policy and is intended to satisfy the affirmative defense requirements of Rule 10b5-1(c) under the Exchange Act. The Krebs 10b5-1 Plan provides for the sale of up to 250,000 shares of the Company’s common stock between August 31, 2026 and February 28, 2027, pursuant to terms specified in the Krebs 10b5-1 Plan.
Casey M. Nault
Executive Vice President, General Counsel and Secretary
Adopted 10b5-1 plan May 19, 2026 10-Q Aug 5, 2026
What the company wrote
On May 19, 2026, Casey M. Nault, Executive Vice President, General Counsel and Secretary, adopted a new trading arrangement for the sale of the shares of the Company’s common stock (the “Nault 10b5-1 Plan”). The Nault 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s Insider Trading Policy and is intended to satisfy the affirmative defense requirements of Rule 10b5-1(c) under the Exchange Act. The Nault 10b5-1 Plan provides for the sale of up to 240,000 shares of the Company’s common stock between August 18, 2026 and May 8, 2028, pursuant to terms specified in the Nault 10b5-1 Plan.
Anne Beckelheimer
Senior Vice President, Tax and Treasurer
Adopted 10b5-1 plan May 11, 2026 10-Q Aug 5, 2026
What the company wrote
On May 11, 2026, Anne Beckelheimer, Senior Vice President, Tax and Treasurer, adopted a new trading arrangement for the sale of the shares of the Company’s common stock (the “Beckelheimer 10b5-1 Plan”). The Beckelheimer 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s Insider Trading Policy and is intended to satisfy the affirmative defense requirements of Rule 10b5-1(c) under the Exchange Act. Ms. Beckelheimer was not an officer of the Company as defined by Rule 16a-1(f) of the Securities Exchange Act of 1934 at the time the Beckelheimer 10b5-1 Plan was adopted. However, as noted in Part II, Item 5(a) above, the Company intends to appoint Ms. Beckelheimer to be an officer of the Company effective August 10, 2026. The Beckelheimer 10b5-1 Plan provides for the sale of up to 20,000 shares of the Company’s common stock between June 11, 2026 and February 25, 2027, pursuant to terms specified in the Beckelheimer 10b5-1 Plan
Mitchell J. Krebs
Chairman, President and Chief Executive Officer
Ended 10b5-1 plan Sep 8, 2025 10-K Feb 18, 2026
What the company wrote
The trading arrangement for the sale of shares of the Company’s common stock previously adopted by Mitchell J. Krebs, Chairman, President and Chief Executive Officer, on June 6, 2025 (the “June Krebs 10b5-1 Plan”) was terminated on September 8, 2025 (the “June Krebs 10b5-1 Plan Termination Date”) pursuant to the terms specified in the June Krebs 10b5-1 Plan because all 250,000 shares subject to the plan had been sold.
Mitchell J. Krebs
Chairman, President and Chief Executive Officer
Ended 10b5-1 plan Sep 8, 2025 10-Q Oct 29, 2025
Casey M. Nault
Vice President, General Counsel and Secretary
Ended 10b5-1 plan Aug 22, 2025 10-K Feb 18, 2026
What the company wrote
The trading arrangement for the sale of shares of the Company’s common stock previously adopted by Casey M. Nault, Executive Vice President, General Counsel and Secretary, on February 28, 2025 (the “Nault 10b5-1 Plan”) was terminated on August 22, 2025 (the “Nault 10b5-1 Plan Termination Date”) pursuant to the terms specified in the Nault 10b5-1 Plan because all 202,257 shares subject to the plan had been sold.
Casey M. Nault
Senior Vice President, General Counsel and Secretary
Ended 10b5-1 plan Aug 22, 2025 10-Q Oct 29, 2025
Mitchell J. Krebs
Chairman, President and Chief Executive Officer
Ended 10b5-1 plan Jun 5, 2025 10-Q Aug 6, 2025
What the company wrote
On June 5, 2025, Mitchell J. Krebs, Chairman, President and Chief Executive Officer, terminated the trading arrangement for the sale of shares of the Company’s common stock he had previously adopted on February 21, 2025 (the “February Krebs 10b5-1 Plan”) in accordance with Rule 10b5-1 of the Exchange Act. On June 6, 2025, Mr. Krebs adopted a new trading arrangement for the sale of the shares of the Company’s common stock (the “June Krebs 10b5-1 Plan”). The June Krebs 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s Insider Trading Policy and is intended to satisfy the affirmative defense requirements of Rule 10b5-1(c) under the Exchange Act. The June Krebs 10b5-1 Plan provides for the sale of up to 250,000 shares of the Company’s common stock between September 5, 2025 and February 15, 2026, pursuant to terms specified in the June Krebs 10b5-1 Plan.
Casey M. Nault
Senior Vice President, General Counsel and Secretary
Adopted 10b5-1 plan Feb 28, 2025 10-Q May 7, 2025
What the company wrote
On February 28, 2025, Casey M. Nault, Senior Vice President, General Counsel and Secretary, adopted a trading arrangement for sale of shares of the Company’s common stock (the “Nault 10b5-1 Plan”) in accordance with Rule 10b5-1 of the Exchange Act. The Nault 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s Insider Trading Policy and is intended to satisfy the affirmative defense requirements of Rule 10b5-1(c) under the Exchange Act. The Nault 10b5-1 Plan provides for the sale of up to 202,257 shares of the Company’s common stock between June 2, 2025 and February 26, 2027, pursuant to terms specified in the Nault 10b5-1 Plan.
Mitchell J. Krebs
Chairman, President and Chief Executive Officer
Adopted 10b5-1 plan Feb 21, 2025 10-Q May 7, 2025
What the company wrote
On February 21, 2025, Mitchell J. Krebs, Chairman, President and Chief Executive Officer, adopted a trading arrangement for the sale of shares of the Company’s common stock (the “Krebs 10b5-1 Plan”) in accordance with Rule 10b5-1 of the Exchange Act. The Krebs 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s Insider Trading Policy and is intended to satisfy the affirmative defense requirements of Rule 10b5-1(c) under the Exchange Act. The Krebs 10b5-1 Plan provides for the sale of up to 200,000 shares of the Company’s common stock between May 23, 2025 and May 23, 2027, pursuant to terms specified in the Krebs 10b5-1 Plan.
Show the other 3 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 16 filings checked since May 10, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Aug 19, 2026 James Kenneth Thompson
Director
25,000 $523K
Aug 19, 2026 Nault Casey M.
Officer
80,000 $1.8M
Jun 1, 2026 KEN WATKINSON
Officer
39,000 $725K

From the Form 144 XML filed with the SEC, since Jun 1, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CDE/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.